Preferred Label : Darunavir Ethanolate/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fumarate;

NCIt definition : A four-drug fixed combination of the ethanolate salt form of darunavir, a human immunodeficiency virus type 1 (HIV-1) protease nonpeptidic inhibitor; cobicistat, a cytochrome P450 3A (CYP3A) inhibitor; emtricitabine, a nucleoside reverse transcriptase (RT) inhibitor (NRTI) analog of cytidine; and tenofovir alafenamide fumarate, the fumarate salt form of the lipophilic phosphonamidate prodrug of tenofovir, a NRTI analog of adenosine monophosphate, that is used to treat human immunodeficiency virus (HIV) infection. Upon oral administration of darunavir ethanolate/cobicistat/emtricitabine/tenofovir alafenamide fumarate, darunavir selectively targets and binds to the active site of HIV-1 protease and inhibits the dimerization and catalytic activity of HIV-1 protease. This inhibits the proteolytic cleavage of viral Gag and Gag-Pol polyproteins in HIV-infected cells. This inhibition leads to the production of immature, non-infectious viral proteins that are unable to form mature virions, and prevents HIV replication. Cobicistat inhibits CYP3A, thereby limiting the oxidative metabolism of darunavir and increases its systemic exposure. Emtricitabine and tenofovir alafenamide, after being converted in vivo to tenofovir, inhibit the activity of HIV RT by competing with natural deoxyribonucleosides for incorporation into the growing viral DNA chain and resulting in early chain termination. This interferes with the generation of DNA copies of viral RNA, which is necessary for the synthesis of new virions.;

Drug name : Symtuza;

NCI Metathesaurus CUI : CL1407368;

Details


Main resources

You can consult :


https://www.has-sante.fr/jcms/c_2863577/fr/symtuza
2019
false
false
false
France
evaluation of the transparency committee
antiviral agents
Darunavir Ethanolate/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fumarate

---
https://www.has-sante.fr/portail/jcms/c_2863577/fr/symtuza
2018
false
false
false
France
French
drug combinations
treatment outcome
anti-hiv agents
hiv infections
adult
adolescent
administration, oral
Cytochrome P-450 CYP3A Inhibitors
hiv protease inhibitors
reverse transcriptase inhibitors
antivirals for systemic use
evaluation of the transparency committee
insurance, health, reimbursement
Tenofovir
Darunavir
Cobicistat
tenofovir alafenamide
Emtricitabine
tenofovir alafenamide
adenine
Darunavir Ethanolate/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fumarate

---
https://www.has-sante.fr/portail/jcms/c_2886171/fr/symtuza-darunavir-/cobicistat-/emtricitabine-/tenofovir-alafenamide-association-d-antiviraux
2018
false
false
false
France
French
drug combinations
treatment outcome
anti-hiv agents
hiv infections
adult
adolescent
administration, oral
Cytochrome P-450 CYP3A Inhibitors
hiv protease inhibitors
reverse transcriptase inhibitors
antivirals for systemic use
evaluation of the transparency committee
insurance, health, reimbursement
guidelines for drug use
Tenofovir
Darunavir
Cobicistat
tenofovir alafenamide
Emtricitabine
tenofovir alafenamide
adenine
Darunavir Ethanolate/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fumarate

---
https://www.ema.europa.eu/medicines/human/EPAR/Symtuza
2017
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug combinations
Darunavir
Cobicistat
drug approval
europe
treatment outcome
Emtricitabine
tenofovir alafenamide
anti-hiv agents
anti-hiv agents
hiv infections
product surveillance, postmarketing
adult
adolescent
administration, oral
tablets
Cytochrome P-450 CYP3A Inhibitors
Cytochrome P-450 CYP3A Inhibitors
hiv protease inhibitors
hiv protease inhibitors
reverse transcriptase inhibitors
reverse transcriptase inhibitors
tenofovir alafenamide
antivirals for systemic use
pregnancy
breast feeding
drug interactions
drug evaluation, preclinical
Tenofovir
Darunavir
Cobicistat
tenofovir alafenamide
Emtricitabine
tenofovir alafenamide
adenine
Darunavir Ethanolate/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fumarate

---
Nous contacter.
28/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.